Trade Spyre Therapeutics Inc. - SYRE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1400 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 15.235 |
| Open | 14.91 |
| 1-Year Change | 27.23% |
| Day's Range | 14.91 - 15.69 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 15.2350 | -0.4850 | -3.09% | 15.7200 | 16.0300 | 15.1800 |
| Mar 31, 2025 | 16.0750 | -1.2750 | -7.35% | 17.3500 | 17.3500 | 16.0600 |
| Mar 28, 2025 | 17.8800 | 0.6400 | 3.71% | 17.2400 | 18.1900 | 17.1900 |
| Mar 27, 2025 | 17.6000 | 0.9200 | 5.52% | 16.6800 | 17.8700 | 16.6800 |
| Mar 26, 2025 | 16.9400 | -1.1100 | -6.15% | 18.0500 | 18.5700 | 16.8600 |
| Mar 25, 2025 | 18.1100 | -0.8500 | -4.48% | 18.9600 | 19.0000 | 17.4500 |
| Mar 24, 2025 | 18.9500 | 0.8400 | 4.64% | 18.1100 | 19.3400 | 17.9300 |
| Mar 21, 2025 | 18.1200 | 0.4700 | 2.66% | 17.6500 | 18.4700 | 17.4200 |
| Mar 20, 2025 | 18.1000 | 0.4700 | 2.67% | 17.6300 | 18.5400 | 17.5600 |
| Mar 19, 2025 | 18.3300 | 0.5300 | 2.98% | 17.8000 | 18.7400 | 17.6900 |
| Mar 18, 2025 | 17.8300 | -0.3200 | -1.76% | 18.1500 | 18.5700 | 17.8000 |
| Mar 17, 2025 | 18.4800 | 0.6200 | 3.47% | 17.8600 | 18.8300 | 17.8600 |
| Mar 14, 2025 | 17.9700 | -0.1600 | -0.88% | 18.1300 | 18.3900 | 17.8000 |
| Mar 13, 2025 | 17.9200 | -0.4500 | -2.45% | 18.3700 | 18.8500 | 17.4400 |
| Mar 12, 2025 | 18.8450 | 0.2650 | 1.43% | 18.5800 | 19.3400 | 18.2800 |
| Mar 11, 2025 | 18.4700 | -0.3400 | -1.81% | 18.8100 | 19.0200 | 17.2000 |
| Mar 10, 2025 | 18.5900 | -0.3300 | -1.74% | 18.9200 | 19.2100 | 18.1200 |
| Mar 7, 2025 | 19.4300 | -0.5200 | -2.61% | 19.9500 | 20.9200 | 19.3700 |
| Mar 6, 2025 | 20.4450 | 1.8950 | 10.22% | 18.5500 | 20.5000 | 18.5500 |
| Mar 5, 2025 | 19.4150 | 0.4150 | 2.18% | 19.0000 | 19.4800 | 17.8400 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Aeglea Bio Therapeutics Company profile
About Aeglea Bio Therapeutics Inc
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human enzyme therapeutics to benefit people with rare metabolic diseases. The Company’s product candidates include pegzilarginase and AGLE-177. The Company's lead product candidate, pegzilarginase, is a recombinant human arginase one that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase one Deficiency. Its engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. The Company is evaluating Pegzilarginase in a global pivotal Phase III PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and in a Phase II open-label extension study for patients with Arginase One Deficiency. Its AGLE-177, is a novel PEGylated, or polyethylene glycol modified, human enzyme engineered to reduce Homocystinuria.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aeglea Bio Therapeutics Inc revenues increased from $0K to $18.7M. Net loss decreased 19% to $65.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$1.52 to -$1.33.
| Industry: | Bio Therapeutic Drugs |
221 Crescent Street
Suite 105
WALTHAM
MASSACHUSETTS 02453
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com